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ABSTRACT 
Aim: To assess the clinical characteristic of CD as well as correlation of symptoms and the degrees of intestinal mucosal 
lesions in Iranian children. 
Background: Microscopic Enteritis (Marsh 0-II) is associated with malabsorption.  
Patients and methods: From August 2005 to September 2009, 111 cases with malabsorption and classical 
gastrointestinal symptoms were evaluated. 
Results: The mean (±SD) age of children with CD was 4.9±3.5 years (range, 6 month - 16 years) and the mean duration 
of symptoms was 8 ± 20.5 months. 50 cases (45%) were female and 61 cases (55%) were male. The most common 
clinical presentation was failure to thrive in 72%, chronic diarrhea in 65.8% and Iron deficiency anemia in 59.5%. 
Sensitivity of EMA was 100% in patients with Marsh IIIb and Marsh IIIc. EMA was also positive in 77% of cases with 
Marsh 0, 18% in Marsh I, 44% in Marsh II and 81.8% in patients with Marsh IIIa. 
Conclusion: Histopathology did not reflect the severity of gluten sensitivity. This would suggest that the degree of 
intestinal mucosal damage might not be a reliable prognostic factor. Significant symptoms can be present with minor 
histological change on biopsy. 
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Introduction  
1 Microscopic enteritis (ME) is the stage of 
microscopic and sub-microscopic changes 
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(Marsh 0-II) associated with the symptoms of 
micronutrient deficiencies. It is characterized 
by subtle mucosal abnormalities without 
prominent inflammation, villous effacement, 
erosions or ulcerations on conventional light 
microscopy (1).  
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Classical coeliac disease (CD) with 
diarrhea, abdominal distension and failure to 
thrive is uncommon in western studies, and 
atypical forms (2) are more frequently found (3). 
The literature lacks data on CD in cohorts with 
severe malabsorption.  Serological tests are often 
used as a powerful screening tool for CD and they 
proved to have a superior value compared to 
milder enteropathy (4-6). In developing countries 
many individuals with even classical CD may still 
remain undiagnosed due to poor access to 
intestinal biopsy and serology (7, 8). This lack of 
access to investigations may contribute to patients 
presenting with overt malabsorption. Evidence 
shows that coeliac disease develops gradually 
from small bowel mucosal inflammation to crypt 
hyperplasia and only a few patients might develop 
overt villous atrophy. Milder enteropathy like 
microscopic enteritis (1)  seems to be a common 
presentation form of CD. Progress has been made 
toward the hypothesis that a form of gluten 
intolerance exists that’s different from CD, 
defined as non-coeliac gluten sensitivity (NCGS) 
(9, 10), and it is estimated that for every person 
who has CD, there are at least six or seven people 
who have GS. Therefore, wheat allergy, CD, and 
GS combined together may affect about 10% of 
the general population. Whether CD or NCGS, 
unfortunately milder enteropathy is usually 
ignored and under-reported by pathologists (11). 
In developing countries the problem is even worse 
as CD with borderline enteropathy is not routinely 
considered as a likely diagnosis because some 
etiologies such as post-infectious diarrhea, 
malnutrition and parasitosis are more obvious 
causes (12). However, ruling out other etiologies 
would not make the diagnostic procedures much 
easier as milder enteropathy has a non-specific 
nature. In recent years emphasis has shifted away 
from CD in the context of being a treatable entity 
only when associated with severe mucosal 
damages. This is because recognizing the atypical 
presentation of CD and recently described non-
coeliac gluten sensitivity has introduced a new 
insight in treatment strategy.  It is still not 
sufficiently clear why some patients present with 
diarrhea and others may be subclinical (13, 14). 
The pathologic spectrum of the mucosal 
abnormalities seen on small intestinal biopsies, 
range from microscopic enteritis (Marsh 0-II) to 
macroscopic form (Marsh IIIa-c) (1) but mostly 
uncorrelated with symptoms. The term of 
macroscopic enteritis points to the macro-
endoscopic characteristic of Marsh III-a-c lesions 
that could be visualized by endoscope (15). 
Despite the fact that microscopic enteritis (Marsh 
0-II) represent the most common presentation 
form of CD, treatment of this condition is still 
based on severe mucosal damages like Marsh III  
(1, 16, 17). There are little data concerning this 
issue in Iranian children. A better understanding of 
the pathology behind the symptoms will diminish 
the role of histology (18) for diagnosis of CD. 
This will open a new prospect for the treatment of 
symptomatic patients with milder enteropathy. 
The aim of this study was to assess the clinical 
characteristic of CD patients as well as 
relationship between symptoms and the severity of 
intestinal mucosal lesions.  
 
Patients and Methods 
Study design and inclusion criteria 
From August 2005 to September 2009, 111 
subjects with malabsorption and classical 
gastrointestinal symptoms were evaluated in three 
Pediatric Gastroenterology units in Iran. (see flow 
chart) Patients were referred because of 
gastrointestinal symptoms (failure to thrive, 
chronic diarrhea, abdominal pain, bloating and 
constipation) or extraintestinal reasons (iron 
deficiency anemia, abnormal transaminase level 
and short stature). Diarrhea that persists for more 
than 2 weeks was considered chronic. Iron 
deficiency anemia and failure to thrive was defined 
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according to CDC criteria and Global Database on 
Child Growth and Malnutrition (19, 20).  
The following clinical variables were collected 
through a questionnaire: age and gender, duration 
of symptoms, clinical findings, growth parameters 
(height and weight Z scores) laboratory and 
intestinal biopsy findings. Before referral, most of 
these cases were treated with multiple courses of 
anti-parasitic drugs, a common practice for the 
treatment of chronic d iarrhea and failure to thrive 
in Iran by general physicians. All of subjects had 
at least a three -month period of previous ingestion 
of gluten. All findings were recorded on a 
database sheet designed for the study.  
Exclusion criteria 
The children with irregular follow up, bloody 
diarrhea, missing data, or chromosomal disorder 
were excluded from study. 
Investigation 
The study group underwent investigations 
including blood tests, coeliac serology and 
gastroscopy with duodenal biopsy (GD2). All 
serum samples were collected at the time of 
diagnosis when the patients were receiving a 
normal diet without any restrictions. Routine 
hematology, biochemical and serology tests 
[endomysial antibody (EMA)] were performed. In 
order to exclude selective IgA deficiency, total 
IgA level by immunodiffusion method was 
determined in all 111 patients who underwent 
UGIE. IgA deficiency was ruled out in all cases.  
Ethical approval and consent 
The study was approved by Ethical and 
Research Center for Children and Adolescences 
Health at Zahedan University of Medical 
Sciences. Informed consent from the parents of all 
subjects who agreed to participate in this study 
was obtained before collecting samples and 
endoscopy. 
Intestinal biopsy and pathology 
Upper gastrointestinal endoscopy (UGIE) by a 
pediatric fiberoptic endoscope was performed in 
111 symptomatic patients with negative tests for 
parasitic illnesses. During the procedure, 4 
biopsies from different part of duodenum were 
obtained and correctly oriented on acetate filters. 
The tissue obtained by biopsy was examined by 
expert pathologists who were not aware of clinical 
findings. Biopsy specimens were evaluated 
according to Marsh classification 1992, as revised 
Table 1.  Histological classification for coeliac disease 
Classification Histology IEL/100 enterocytes Crypts Villi Endoscopy
Normal mucosa Marsh 0 
Normal 
<25/100 EC Normal N Normal 
Microscopic Enteritis Marsh 0 SME (Microenteropathy) <25/100 EC Normal N Normal 
Marsh I 
Lymphocytic enteritis  
>25/100 EC Normal N Normal 
Marsh II 
Hypeplastic stage  
>25/100 EC Hyperplastic N Normal 
Macroscopic Enteritis Marsh IIIa >25/100 EC Hyperplastic PVA Abnormal 
Marsh IIIb >25/100 EC Hyperplastic STVA Abnormal 
Marsh IIIc >25/100 EC Hyperplastic TVA Abnormal 
Marsh IV <25/100 EC NCD, HP  TVA Abnormal 
SME= sub-microscopic enteritis, N= normal, EC= enterocytes, PVA= Partial villous atrophy, STVA= Subtotal 
Villous atrophy, TVA= Total villous atrophy, NCD, HP= Normal crypt depth, but hypoplasia 
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by Rostami et al (21, 22). (Table 1) Serology was 
performed after Endoscopy 
Diagnosis and treatment: The diagnosis was 
made based on clinical symptoms, serology 
including total serum IgA, IgA EMA and duodenal 
biopsy. All patients were given a dietary chart 
form including written information about foods to 
be avoided (wheat, barley, rye, oat) and received 
iron and multivitamin as a supplementation. The 
importance of compliance with a GFD was 
repeatedly explained to the parents and the child. 
Gluten-free diet (GFD) (23) was recommended for 
all children with Macroscopic enteritis (Marsh 
IIIa-c) and those with Microscopic enteritis 
(Marsh I-II) with positive serology (Figure 1).  
All serum samples were collected at the time of 
diagnosis when the patients were receiving a 
normal diet without any restrictions. Routine 
hematology, biochemical and serology tests 
endomysial antibody (EMA) were performed. In 
order to exclude selective IgA deficiency, total 
IgA level by immunodiffusion method was 
determined in all 111 patients who underwent 
UGIE. IgA deficiency was ruled out in all cases.  
Statistical analysis 
We calculated frequencies and percentages for 
qualitative variables and means, medians and 
standards deviations for quantitative variables. The 
links between qualitative variables were assessed 
using Chi square test. P value <0.05 were considered 
significant. Data are expressed as mean ± SD.  
 
Results 
Data analysis 
From 111 symptomatic patients with negative 
screening for parasites, 84 cases fulfilled the 
diagnostic criteria for having CD. This included all 
symptomatic patients with enteropathy (Marsh I-
IIIc) and positive serology. Those patients with 
macroscopic enteritis (Marsh IIIa) and negative 
serology were also considered as CD. However, 
patients with microscopic enteritis (Marsh 0-II) 
and negative serology were not diagnosed as CD. 
Those patients with milder enteropathy (27/111) 
and negative serology could have been NCGS (24) 
and will be followed up under the test of time 
strategy. Summary of data analysis has shown in 
table 2. 
 
 
Figure 1 . Microscopic Enteritis  (Marsh I and Marsh II); 
Normal villi with pathological increase of T Lymphocytes (A) 
with cript hyperplasia (B); A H&E x 10 B CD3 x10. This form of 
mucosal abnormality is overlooked by many pathologists. 
 
General characteristics  
The mean ± SD age of children with CD was 
4.9 ± 3.5 years (range, 6 month - 16 years) and the 
mean duration of symptoms was 8 ± 20.5 months. 
50/111 cases (45%) were female and 61/111 cases 
(55%) were male. The most common clinical 
presentation was failure to thrive in 80/111(72%) 
cases, chronic diarrhea in 73/111(65.8%) and iron 
deficiency anemia in 66/111(59.5%) cases 
followed by abdominal pain in 62/111(55.9%), 
fatty stool and abdominal distension in 
54/111(48.6%) (Table 3). An association with a 
family history of diabetes, hypothyroidism and 
CD was found in 4, 7 and 13 cases respectively. 
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Among subjects with coeliac disease, 2 cases of 
hypothyroidism, 1 case of cirrhosis and diabetes 
were found. Chronic diarrhea, constipation failure 
to thrive, and short stature were significantly more 
prevalent in patients with Marsh I compared to 
those with Marsh III (Figure 2). 
 
Laboratory and Histopathology findings   
IgA EMA was positive in 68/98 of subjects. 
Histology revealed Marsh 0 in 13 cases (11.7%), 
Marsh I in 11 cases (9.9%), Marsh II in 27 cases 
(24.3%), Marsh IIIa in 44 cases (39.6 %), Marsh IIIb 
in 10 cases (9 %) and Marsh IIIc in 6 cases (5.4 %) of 
patients, respectively. Positive EMA were found in 
10/13(76.9%) of patients with Marsh 0, 2/11 (18%) of 
patients with Marsh I, 12/27 (44.4%) in Marsh II and 
36/44 (81.8%) with Marsh IIIa. Sensitivity of EMA 
was 100% in patients with Marsh IIIb and Marsh IIIc 
(Table 2). Chronic diarrhea, constipation failure to 
thrive, and short stature were significantly more 
prevalent in patients with Marsh I compared to those 
with Marsh III (Table 3).  
 
Discussion 
The present study demonstrates that 
Microscopic Enteritis (ME) is the most common 
Table 2. Histology and serology in 111 patients with enteropathy according to Modified Marsh classification 
Histology Marsh 0 
N=13(11.7%) 
Marsh I 
n=11 (9.9%) 
Marsh II 
n=27 (24.3%) 
Marsh IIIa 
n=44 (39.6%) 
Marsh IIIb 
n=10 (9%) 
Marsh IIIc 
n=6 (5.4%) 
Total 
EMA +ve 10/13(76.9%) 2/11 (18%) 12/27 (44.4%) 36/44 (81.8%) 10/10 (100%) 6/6 (100%) 76/111 (68.5%)
EMA  -ve 3/13(23%) 9/11 (82%) 15/27(55.5%) 8/44(18%) 0 0 35/111 (31.5%)
 Mic.E* Mic.E Mic.E Mac.E**          Mac.E               Mac.E  
* Microscopic Enteritis                 ** Macroscopic Enteritis 
 
Table 3. Comparing clinical findings between Marsh I-II and Marsh IIIa-c in 111 patients with malabsorption 
syndrome and  abnormal histology  
Variable Marsh 0 
N=13/111 
Marsh I 
N=11/111 
Marsh II 
N=27/111 
Marsh IIIa-c 
N=60/111 
p-value 
chronic diarrhea 
3 (23%) 9(82%) 18(66.6%) 43 (71.7%) 0.005 
Failure to thrive  7(53.8%) 9(81.8%) 20(74%) 44(73.3%) 0.43 
Short stature 7(53.8%) 7(63.6%) 15 (70.3%) 33(55%) 0.96 
Abdominal pain 5(38.5%) 4(36.4%) 17(63%) 36(60%) 0.24 
Abdominal distension 4(30.8%) 5(45.5%) 15(55.5%) 30(50%) 0.52 
Fatty stool 1(7.7%) 4(36.4%) 10(37%) 39(65%) 0.001 
Decreased appetite 4(30.8%) 4(36.4%) 10(37%) 30(50%) 0.56 
constipation 3(23%) 4(36.4%) 6(22.2%) 3 (5%) 0.01 
vomiting 2(15.4%) 4(36.4%) 5(22.7%) 21(35%) 0.27 
rickets 0 0 3(11.1%) 11(18.3%) 0.16 
Tibial edema 0 0 1(3.7%) 6(10%) 0.54 
Anemia 3(23%) 4(36.4%) 13(48.1%) 46(76.7%) 0.001 
EMA 10(79.9%) 2(18.2%) 12(44.4%) 52(86.7%) 0.001 
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histological presentation of CD. A high percentage 
of patients with marsh I had diarrhea and other 
clinical symptoms of overt malabsorption but 
without evidence of mucosal atrophy. This may 
suggest that histology doesn’t reflect the severity 
of disease and the degree of damages in intestinal 
mucosa might not be a reliable prognostic factor. 
This study also highlights that sensitivity of EMA 
may be increased by grade of histopathology. 
Despite the limitation of sensitivity of serology, 
EMA was positive in a significant number of 
patients with ME. This may suggest that serology 
is a far more reliable marker for CD compared to 
histology with milder enteropathy.   
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Figure 2. Clinical presentation in microscopic enteritis 
(Mi ent, Marsh I) compared to macroscopic enteritis 
(Mac ent, Marsh IIIa-c) in percentage. Chronic 
diarrhea, constipation, failure to thrive, short status 
 
Conflicting reports exist on the distribution of 
lesions in CD along the small bowel mucosa and 
the relationship between symptoms and the length 
of lesions. However, despite the previously belief, 
symptomatology in CD does not seems to be 
related to the degree or length of affected bowel 
(5, 25). Some studies that have attempted to 
correlate the degree of villous atrophy with the 
mode of clinical presentation suggest patients with 
mild enteropathy of any kind with positive 
antibodies may experience clear gluten-induced 
symptoms (17, 25), and the severity of CD doesn’t 
reflect in the dept or the length of mucosal 
abnormalities (26, 27). 
The lack of relationship between pathology and 
symptoms was impressively supported by our 
data. We show that the percentage of patients with 
diarrhea, constipation and failure to thrive was 
even higher in Marsh I patients compared to marsh 
III. Anemia and positivity for autoantibodies were 
the only parameters that significantly correlated 
with the macroscopic lesions (Marsh III) in this 
study. Although we are not quite sure why 
sensitivity of serology is co-relating so closely 
with the degrees of mucosal abnormalities (22, 28-
31) (Fig 3) small bowel inflammation is not 
reported only as severe (Marsh III) in anemic 
patients in other studies (27, 32).  
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 Figure  3. Sensitivity of serology (%) in patients with 
different degrees of mucosal abnormalities 
 
Interestingly 10/13 symptomatic patients with 
Marsh 0 had positive EMA. It is very unlikely that 
these symptomatic cases with malabsorption who 
were extensively investigated for other conditions 
to be false positive. As the depth, length or 
degrees of the mucosal abnormality do not seem to 
correlate with the severity of symptoms, should 
there be a different explanation for malabsorption 
syndrome in all cases with normal, mild and 
severe enteropathy? Accumulated evidence 
suggest that the gluten-sensitized lymphocytes in  
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the mucosa (33) have the crucial role in the 
pathogenesis and they give real aspect of what CD 
means, irrespective of mucosal damages. In other 
words it seems that the sensitized mucosal 
lymphocytes even when within normal range (26, 
27), or something that correlates closely with that 
state of sensitivity are the key factors not only in 
pathogenesis but also in the genesis of the 
symptoms.  
This hypothesis was proved with the range of 
severe symptoms of our patients presenting with 
ME. Low specificity would be other explanation 
but not for EMA as this auto-antibody are 
extremely specific for CD. Even in absence of 
mucosal abnormalities subtle systemic and local 
inflammatory factors are implicated in the genesis 
of anemia and suggest that pro-inflammatory 
cytokine TNFa inhibits at the level of the 
enterocytes affects the uptake of the 
micronutrients like iron (34, 35) or phosphate (36) 
in patients with microenteropathy. It seems that 
malabsorption in CD is secondary to inflammation 
and cytokines stimulation. This theory would 
perhaps explain why our Marsh 0-II patients with 
non-coeliac gluten sensitivity may behave like full 
blown CD (24). Focusing on symptomatology in 
choosing the candidate for therapy seems to be a 
better strategy than concentrating on the degrees 
of the mucosal abnormalities. The lack of 
significant severity of disease in patients with 
Marsh III compared to Marsh I in our study would 
be in favor of such a strategy. Similar to other 
studies (26, 37) children in both groups presented 
with classical picture of coeliac disease and the 
extent of visible enteropathy did not explain 
differences in clinical presentation. Our patients 
had typical symptoms like growth impairment 
with positive or negative antibodies and anemia. 
We clearly experienced that the degrees of 
intestinal mucosal abnormalities alone are not 
reliable predictors of disease behavior. The quality 
of life of the symptomatic cases with Marsh I and 
II with CD or NCGS could be dramatically 
improved by introducing a gluten-free diet (32, 38, 
39). The overall aim should be treating the 
symptoms whether full blown CD or NCGS rather 
than treating the medical terms like villous 
atrophy. The question for the future agenda would 
be how far symptomatic, (40) NCGS with Marsh 
0-II would benefit from a gluten free diet after 
exclusion of other causes for their 
microenteropathy.  
Although the size of our study was small but 
nonetheless our results are adding solid evidence 
to the existing literature to emphasize the 
superiority of serology compared to milder 
histology like ME in diagnosing CD. The other 
limitation of our study was the lack of possibility 
of follow up of our patients and implementing a 
GFD in NCGS as the study was performed before 
description of this new entity. But again this 
would not prevent us to suggest that treatment of 
gluten sensitive cases should not be based on 
villous atrophy as histology does not always 
reflect the severity of CD.  
The lack of awareness between clinicians is 
one of the main reasons for delaying the diagnosis 
and treatment of NCGS and CD cases with 
microenteropthy.  
It is time to acknowledge, believe and act to 
shift the paradigm from villous atrophy to the sole 
presentation form of CD and NCGS in order to 
make a difference in life quality of symptomatic 
patients with or without milder enteropathy. As a 
consequence it is necessary, today, to motivate the 
pathologists to look at new morphological aspects 
of this precocious forms of the disease, for 
example a re-evaluation of the value of 25/100 
epithelial cells of T lymphocytes as the barrier of 
normality strictly depending on the number and 
quality of the biopsies and the experience of the 
pathologist. It is important to keep in mind that the 
biopsy is a photograph of a moment in the history 
of disease and today with the concept of 
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microscopic enteritis, the sensation is that 
everything starts with T cells stimulations that 
start the inflammation process in the lower part of 
the mucosa  and then progressively in the surface 
epithelium. This is the natural history of pre-
macroscopic lesions implicated in malabsorption 
related symptoms with no management place in 
the current guidelines.  A larger scale study would 
be required to assess further the pathological 
modalities, the clinical characteristics/implications 
and long term complications. 
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